SCHEMBL172126

SCHEMBL172126

COC(=O)c1cc(NC(=O)OC(C)(C)C)n(CCO)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.39
ATR Q13535 1/20 0.38
CNR2 P34972 3/20 0.36
CNR1 P21554 2/20 0.36
BRD9 Q9H8M2 1/20 0.35
ITGA4 P13612 1/20 0.35
ITGB7 P26010 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
PTGER1 P34995 1/20 0.34
SCD O00767 1/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28626032 0.89 ABCB1 (0.38) MAPK14PTGDR2PTGER1NPC1RAB9A
SCHEMBL25594883 0.89 MAPK14 (0.39) MAPK14CNR2CNR1BRD9ITGA4
SCHEMBL25407400 0.84 MAPK14 (0.46) MAPK14ATRCNR2BRD9CCNC
SCHEMBL798842 0.83 GAA (0.49) MAPK14BRD9PTGDR2PTGER1CCNC
SCHEMBL171962 0.83 CNR2 (0.38) MAPK14ATRCNR2CNR1NPC1
SCHEMBL20852263 0.83 ATR (0.36) MAPK14ATRCNR2BRD9PTGDR2
SCHEMBL22102483 0.82 MAPK14 (0.40) MAPK14CNR1BRD9ITGA4ITGB7
SCHEMBL25599482 0.81 PPARA (0.44) MAPK14CNR2BRD9PTGER1SCD
SCHEMBL20852265 0.74 CYP2C9 (0.40) MAPK14BRD9PTGDR2PTGER1SCD
SCHEMBL25401903 0.74 MAPK14 (0.45) MAPK14CNR2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS SCHRÖDINGER, INC. 2023-06-01 US disclosed
WO-2023086319-A1 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed
US-9650371-B2 Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity SHIONOGI & CO., LTD. (JP) 2017-05-16 US disclosed
US-20160326158-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2016-11-10 US disclosed
EP-2426135-A1 UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-03-07 EP disclosed
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 US disclosed
EP-2327704-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY Shionogi&Co., Ltd. (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160326158-A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY BACE1, BACE2, APP MAPK14 3283/4885ATR 2873/4885CNR2 2039/4885
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY PIK3R5, PIK3R4, PIK3R1 MAPK14 86/4885ATR 873/4885CNR2 4502/4885
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B MAPK14 596/4885ATR 1679/4885CNR2 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.